Fig. 1From: Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE studyMean change from baseline at Month 6 (a) and Month 12 (b) in CDAI score for IV golimumab with and without methotrexate (last observation carried forward for missing data) in biologic-naïve and biologic-experienced patients. CDAI Clinical Disease Activity Index, IV intravenous, SD standard deviationBack to article page